| Drug Name | ( Genvoya ®(Emtricitabine, Elvitegravir , Cobicistat ,Tenofovir, Alafenamide |
|---|---|
| Drug Class |
Anti-viral
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Infectious disease
|
| Risk |
Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy |
| Dear Healthcare provider letter DHPC |
|